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A transcript of unknown function, regulated by fasting and feeding, was identified by micro-
array analysis. The transcript is up-regulated in the fasting state. An 1168-bp cDNA was
cloned from rat hypothalamus and sequenced. This sequence is consistent with adipogenesis
down-regulating transcript 3 (AGD3) (also known as human OCC-1) mRNA. A protein
sequence identical to AGD3 was determined by mass spectrometry. In the rat brain, AGD3 mRNA
is distributed in the arcuate nucleus, ventromedial hypothalamus, amygdaloid nuclei, hippocam-
pus, and somatic cortex. Double in situ hybridisation showed that AGD3 mRNA is co-localised
with pro-opiomelanocortin and neuropeptide Y in arcuate nucleus neurones. AGD3 binds with
insulin receptor substrate 4 and increases insulin-stimulated phospho-Akt and regulates AMP-
activated protein kinase and mammalian target of rapamycin downstream target S6 kinase
phosphorylation.
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Obesity and being overweight represent major public health prob-
lems. These conditions affect morbidity and mortality as factors
contributing to diabetes mellitus, cardiovascular disease, pulmonary
disease, osteoarthritis and several types of cancers. Research has
established the hypothalamus as a crucial site in controlling body
weight. Peripherally produced hormones such as insulin, as well as
nutrients such as glucose and fatty acids, communicate energy sta-
tus to hypothalamic centres (1–3). The structure of the hypotha-
lamic arcuate nucleus (ARC) is consistent with its role as an
integrative centre in energy homeostasis. Neuroanatomical studies
have identified two distinct populations of ARC neurones (4). The
first population expresses the orexigenic neuropeptide Y (NPY) and
agouti-related peptide. The second group of neurones expresses
anorexigenic neuropeptides cocaine- and amphetamine-related
transcript (CART) and pro-opiomelanocortin (POMC) (4,5).
Gene analysis using microarrays and high-throughput sequencing
has been utilised extensively as a platform for biological explora-
tion, including conditions associated with obesity. Using this
approach, a previous report from our laboratory confirmed the dif-
ferential expression of several neuropeptides associated with fasting
and obesity (6,7). The study also suggested that intracellular regula-
tory genes are involved in energy homeostasis and are differentially
regulated during fasting and feeding states. Over the past decade,
microarray studies of cDNAs have revealed thousands of novel
transcripts (8). When the functional roles have been unclear, these
have been designated as transcripts of unknown function (TUF). It
is widely assumed that the majority of TUFs are noncoding RNAs
(9,10). These noncoding RNAs may regulate gene function as
microRNAs, as small nucleolar RNAs or through noncoding repres-
sion of transcription factors (10). We identified a TUF as being
strongly up-regulated in the rat ARC by fasting. In the present
study, this TUF was identified as derived from an mRNA of 1.2 kbp
identical to the previously described overexpressed in colon cancer-
1 (11) and, recently, adipogenesis down-regulating transcript 3
(AGD3) (12). The AGD3 mRNA has an open-reading frame that pro-
duces a 63-amino acid peptide. AGD3 is expressed in brain areas
relevant to feeding behaviour and is involved in cellular signalling




Anti-Myc antibody-conjugated agarose was purchased from Bethyl Labora-
tories (Montgomery, TX, USA). Anti-Myc monoclonal antibody was pur-
chased from BD Bioscience (Palo Alto, CA, USA). Protein A SepharoseTM
CL-4B was obtained from GE Healthcare (Uppsala, Sweden). Anti-human
insulin receptor substrate 4 (IRS4) antibody (EP907Y) was obtained from
Abcam (Cambridge, MA, USA). Phospho-Akt (Thr308) antibody, Akt antibody
phospho-AMP-activated protein kinase (AMPK)a (Thr172) antibody, AMPKa
antibody, phospho-S6 (Ser235/236) antibody and S6 ribosomal protein
antibody were obtained from Cell Signalling Technologies (Beverly, MA,
USA).
Cell culture
Human embryonic kidney (HEK293) cells were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM) with 10% foetal bovine serum (FBS) with
100 U/ml penicillin and 100 lg/ml streptomycin. Human neuroblastoma
(SK-N-AS) cells were obtained from ATCC (Manassas, VA, USA) and were cul-
tured in ATCC-formulated DMEM with 1% non-essential amino acids, 10%
FBS, 100 U/ml penicillin and 100 lg/ml streptomycin. Human colorectal
adenocarcinoma (CACO-2) cells were obtained from Sigma-Aldrich (St Louis,
MO, USA) and were cultured in Eagle’s minimal essential medium. with
2 mM glutamine, 1% non-essential amino acids and 10% FBS. Mouse hypo-
thalamus (GT1-1) cells were cultured in DMEM with 10% FBS containing
100 U/ml penicillin and 100 lg/ml streptomycin.
Animals and experimental protocol
Male Sprague–Dawley rats (Harlan Laboratories, Madison, WI, USA) weigh-
ing 280–300 g were used to study AGD3 expression. Rats were housed in
accordance with the University of Michigan Unit of Laboratory Animal
Medicine guidelines. Five rats were assigned to the fed group and five
rats to the fasted group. Animals in the fed group were allowed free
access to regular rat chow and water. Animals in the fasted group were
food-deprived 48 h but were allowed free access to water. At the end of
48-h period, animals were sequentially euthanised. Whole brain was
removed and frozen. A 2-mm thick section from Bregma 2 to 4 mm
was sliced. The ARC was punched out using a Stoelting brain punch set
(Stoelting Co., Wood Dale, IL, USA). Then, total RNA was isolated from the
samples.
Reverse transcription quantitative PCR (RT-QPCR) was used to examine
changes in rat AGD3 expression. Reverse transcription was performed using
the SuperScript One-Step RT-PCR System with Platinum Taq DNA Polymer-
ase (Invitrogen, Carlsbad, CA, USA). Q-PCR primers were : AGD3: 5′-CCG
ACA GGA GCA GTT AAA GAT G-3/5′-CTT CCA AAT TCA CGA GCA AGC/Probe:
5′-56-FAM/AGA TAA CGC AAT GGC TGG ATA CCC G/36-TAMSp/-3′ and GAP
DH: 5′-ACC ACA GTC CAT GCC ATC AC/5′-CAG CTC TGG GAT GAC CTT GC/
5′-/Probe: 56-FAM/CAC AGC CTT GGC AGC ACC AGT GGA/36-TAMTph/-3′.
GAPDH primers were used as an internal control.
To analyse AGD3 protein expression in ARC, another set of ten rats, five
fed and five fasted, were used. Animals were euthanised. The brain was
removed and a 2 9 2 9 2 mm cube was directly dissected from the ARC
area. The tissue was homogenised in lysis buffer and supernatant was sub-
ject to western blotting.
Cloning of AGD3 cDNA
Our gene microarray study demonstrated that an expressed sequence tag
(EST) was up-regulated by fasting. The EST (Gene Bank accession number
AA925734) was a 189-bp segment. To identify this gene, the EST sequence
was examined using the NCBI database. By aligning the EST sequences with
overlapping cDNA segments, it was extended to a 1215-bp cDNA sequence.
Two pairs of PCR primers linked to the EcoRI and KpnI enzyme sites were
used to clone two portions of the sequence from rat hypothalamus by RT-
PCR. One pair was 5′GGA ATT CCG GGT GGC GCG ATG GGT TGC/5′GGG GTA
CCA GTC TCGT CAG CTT CCT TCT ATG, covering from 117 to 529; another
pair was 5′GGA ATT CAC GCA ATG GCT GGA TAC CCG AGA G/5′ GGG GTA
CCG TTG CTT ACA CTG CCG TCAT, covering from 329 to 1168. The PCR prod-
ucts were sequenced.
AGD3 antibody production
Polyclonal antibodies against the rat AGD3 sequence were generated and
purified by affinity chromatography using a custom service from Invitrogen.
The specificity of the antibodies was characterised using the myc-AGD3
fusion protein.
Construction of expressing AGD3 vector and its small
interfering (si)RNAs
AGD3-pcDNA3.1
The sequence 117–529, which was cloned by RT-PCR from the rat hypothal-
amus and has an open-reading frame coding a 63 amino acids protein, was
subcloned into the pcDNA3.1 using the EcoRI and KpnI sites. The Myc tag
was fused to the N-terminus of AGD3. The correct frame of the construct
was confirmed by DNA sequencing.
AGD3 siRNAs
Three pairs of double-stranded siRNAs targeting the human overexpression
in colon cancer-1 (OCC-1) gene were used. Their sequences were: (i) 5′-CGA
AAG ACA AGU UAA CAA ACU GUC A/5′-UGA CAG UUU GUU AAC UUG UCU
UUC GUA; (ii) 5′-AGC AGC CAA AGA UGU AAC AGA AGA A/5′-UUC UUC
UGU UAC AUC UUU GGC UGC UCC (IDT); and (iii) 5′-CCC UGG GUA CAU
AUU GUU GTT/5′-CAA CAA UAU GUA CCC AGG GTT. Lipofectamine RNAiMax
was used to transfect siRNAs into cells in accordance with the manufac-
turer’s instructions (Invitrogen). After 72 h of transfection, cells were lysed
and supernatants were analysed further.
Identification of the AGD3 transcript
A Pierce Direct IP Kit (Pierce Biotechnology, Rockford, IL, USA) was used to
pull down AGD3 protein from CACO-2 cells. Briefly, AGD3 antibody was
linked to agarose beads and incubated with cell lysates. After overnight
incubation at 4 °C, beads were rinsed thoroughly with wash buffer, and
AGD3 was eluted. Eluates were resolved on 16.5% Tris-Tricine gels (Bio-Rad,
Hercules, CA, USA). Gels were stained with Bio-Safe Coomassie Blue stain
solution. Protein bands recognised by western blotting directed against anti-
AGD3 antibody at the 7-kDa position were subjected to mass spectrometry
analysis.
The protein identification was conducted at the Protein Structure Facility
at the University of Michigan (Ann Arbor, MI, USA). Bands of interest were
excised and the proteins digested in situ with trypsin (Promega, Madison,
WI, USA). Digests were analysed by capillary high-performance liquid chro-
matography-electrospray ionisation tandem mass spectrometry (HPLC-
ESI-MS/MS) on a Thermo Fisher LTQ Orbitrap Velos mass spectrometer
(Thermo Fisher Scientific Inc., Waltham, MA, USA) fitted with a New Objec-
tive Digital PicoView 550 NanoESI source (New Objective, Inc., Woburn, MA,
USA). On-line HPLC separation of the digests was accomplished with an
Eksigent/AB Sciex NanoLC-Ultra 2-D HPLC system (Eksigent, Dublin, CA,
USA): column, PicoFrit (New Objective, Inc.; inner diameter 75 lm) packed
to 15 cm with C18 adsorbent (Vydac, Hesperia, CA, USA; 218MS 5 lm,
300 Å). Precursor ions were acquired in the Orbitrap in centroid mode at
60 000 resolution (m/z 400); data-dependent collision-induced dissociation
(CID) spectra of the six most intense ions in the precursor scan above a set
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threshold were acquired at the same time in the linear trap. Mascot (Matrix
Science Inc., Boston, MA, USA) was used to search the uninterpreted CID
spectra against the SwissProt database (SwissProt_2011_03.fasta). Cross-
correlation of the Mascot results with X! TANDEM (http://www.thegpm.org/tan-
dem/) and determination of protein and peptide identity probabilities were
accomplished using SCAFFOLD (Proteome Software, Inc., Portland, OR, USA).
The thresholds for acceptance of peptide and protein assignments in SCAFFOLD
were 95% and 99.9%, respectively.
In situ hybridisation
In situ hybridisation was conducted using a modification of a previously
described protocol (6). Briefly, a 416-bp PCR generated fragment of the rat
AGD3 was subcloned into pBluescript SK (Stratagene, La Jolla, CA, USA). The
sense primer was: 5′-ACA AGA GGA GAA ACT ACG GAG GAG-3′. The anti-
sense primer was 5′-TGG CCA GGA GGG AAA ACA C-3′. The NPY cDNA
(AI045437) is in pT7T3D-PAC (Invitrogen). The rat POMC plasmid construct
consists of an 833-bp insert in pGEM4Z (Promega).
The 35S-labelled antisense and sense AGD3 RNA probes, and digoxigenin-
labelled antisense and sense NPY and POMC RNA probes, were generated
using standard in vitro transcription methodology.
For single-label in situ hybridisation, the sections were hybridised with
antisense 35S-labelled AGD3 riboprobe. For dual label in situ hybridisation,
the sections were hybridised with antisense digoxigenin-labelled NPY or
POMC and 35S-labelled AGD3 riboprobes.
Male Sprague–Dawley rats were anaesthetised with ketamine/xylazine
and perfused via the ascending aorta with 200 ml of phosphate-buffered
saline (PBS), followed by 200 ml of 4% paraformaldehyde in PBS. The brain
was postfixed for 16 h then transferred to 20% sucrose (20% sucrose in
PBS with 0.02% sodium azide) for 5 days at 4 °C. The brain was embedded
with 20% sucrose and Tissue-Tek OCT (2 : 1) and coronal sections of 14 lm
were cut on a cryostat. The sections were dried overnight at room tempera-
ture and were stored at 80 °C until further processing.
Co-localisation was considered if a cluster of more than 20 silver grains
were above POMC or NYP positive cells.
Dual immunohistochemistry
The sections were rinsed in PBS, 0.5% triton X-100 and blocked in 10%
serum, and then incubated with primary antibodies [rabbit anti-AGD3 (dilu-
tion 1 : 150) and goat anti-POMC (dilution 1 : 100)] overnight at 4 °C. For
AGD3 staining, biotinylated horse anti-rabbit secondary antibody was used
and then visualised with FITC488 (green)-conjugated avidin. To visualise
POMC, Texas Red-conjugated donkey anti-goat secondary antibody was
used. Nuclei were stained with 4′,6-diamidino-2-phenylindole dihydrochlo-
ride (Invitrogen).
Co-immunoprecipitation
HEK293 cells were transfected with myc-AGD3 pcDNA3.1 using Lipofecta-
mine 2000 in accordance with the manufacturer’s instructions (Invitrogen)
and incubated for 48 h. Transfected cells were lysed with PK buffer (50 mM
HEPES, pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 1 mM Na3VO4,
50 mM NaF, 1% Triton X-100, 10% glycerol) and briefly sonicated. The
supernatants of the cell lysates were incubated with protein A or anti-myc-
conjugated beads for 24 h at 4 °C. The beads were washed six times, and
the immunoprecipitants were eluted with sodium dodecylsulphate (SDS)
sample buffer at 95 °C, resolved on by SDS-polyacrylamide gel electrophore-
sis (PAGE), and stained with the Coomassie Blue stain solution (Bio-Rad).
Protein bands missing from the protein A bands were excised from the gel.
The gels were subject to mass spectrometry analysis.
To confirm the interactions between AGD3 and IRS4, which were revealed
by the protein identification analysis, eluates were resolved on SDS-PAGE
gel; the gels were used for western blotting with anti-IRS4 antibody. For the
co-immunoprecipitation of endogenous IRS4 from hypothalamus, rat hypo-
thalamus tissue was homogenised in lysis buffer and the supernatant was
used for immnoprecipitation with protein A and anti-AGD3 antibody. IRS4
was detected with anti-IRS4 antibody.
In the pull down of AGD3 using IRS4, HEK293 cells were transfected
p3xFlag-IRS4-CMV-10 plasmid DNA (13) along with myc-AGD3 pcDNA3.1
DNA. Forty hours after transfection, cells were disrupted by sonication in
lysis buffer and Flag-IRS4 was immunoprecipitated using anti-Flag-M2 anti-
body conjugated agarose (Sigma). After extensive washing, the beads were
resuspended in SDS-PAGE loading buffer and heated at 85 °C for 5 min.
The protein was resolved with SDS-PAGE and transferred to polyvinylidene
membranes. The membranes were blotted with either anti-myc, or anti-Flag
antibody.
Statistical analysis
For Western blots, analysis of densitometry was performed using Kodak 1D
3.6 software (Eastman Kodak, New Haven, CT, USA). Data were analysed
using GRAPHPAD PRISM, version 4.0 (Graphpad Software, San Diego, CA, USA),
and expressed as the mean ± SEM. Differences were analysed by unpaired
two-tailed Student’s t-test. P < 0.05 was considered statistically significant.
Results
Up-regulation of AGD3 in the rat ARC by fasting and
obesity
Gene profiles of the rat ARC were investigated in conditions of
fasting and feeding by utilising microarray analysis (6). This analysis
demonstrated 118 mRNA species that were increased by fasting
relative to the fed state. An EST (gene bank number AA925743) was
significantly increased in the fasted group. Quantitative PCR
confirmed that this EST mRNA was increased two-fold in fasting
animals relative to those in the fed group (Fig. 1A).
We also examined AGD3 transcript expression in the genetically
obese Zucker rat (fa/fa) and the lean Zucker rat. The ARC RNA was
obtained from our previous experiment (6). Compared to the lean
Zucker rat, AGD3 mRNA was up-regulated in the ARC of the fa/fa
rat (Fig. 1B).
Cloning the open-reading frame of rat AGD3
To identify this gene, the EST sequence was examined using the
NCBI database. By aligning the EST sequence with overlapping DNA
segments, it was extended to a 1215-bp DNA sequence. Two pairs
of PCR primers were used to clone two portions of the sequence
and a segment of 1052 bp was confirmed by DNA sequencing. This
rat sequence has high homology with mouse and with the human
OCC-1 gene (11). This sequence also matches a transcript of
unknown function, the AGD3, as reported by Kikuchi et al. (12). The
1052-bp contains several open-reading frames. An open-reading
frame that can translate a 63 amino acid protein was proposed as
a hypothetical protein. The rat hypothetical protein has 86% and
97% sequence identity with the human (NP_001138671) and
mouse (NP_001138670), respectively.
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Identifying the sequence of the hypothetical protein
A rat hypothetical protein was produced, derived from this putative
sequence, and an antibody directed against the hypothetical protein
was created. The antibody recognised a single band when AGD3-
pcDNA3.1 was transfected into HEK293 cells, and recognised
endogenous AGD3 protein in CACO-2 cells, SK-N-AS cells and the
rat hypothalamus (Fig. 2A). By using this antibody, we examined the
protein expression of AGD3 in rat ARC, and the results showed that
AGD3 protein significantly increased in fasted rats (Fig. 2B).
Three anti-AGD3 siRNAs were designed and transfected into
CACO-2 cells. As shown in Fig. 3(A), AGD3 mRNA expression was
inhibited by 90%. AGD3 protein expression was decreased to a
similar degree (Fig. 3B).
The antibody produced against the hypothetical protein was used
to pull down AGD3 protein from CACO-1 cells. The bands that were
recognised by the antibody on western blotting were used to iden-
tify proteins (Fig. 4A). Protein identification by mass spectrometry
revealed the presence of the putative protein, over-expressed in
colon carcinoma (OCC-1_HUMAN; Uniprot accession number
Q8TAD7) in samples 1 and 2 with 100% probability at the protein
level. The unambiguous identification of AGD3 is based on the
observation of seven unique, well sequenced peptides (eight unique
spectra and 11 total spectra) assigned to AGD3 in sample 1. In
sample 2, three unique, well sequenced peptides (four unique spectra
and seven total spectra) were assigned to AGD3. The sequence cov-
erage for AGD3 is 86% in sample 1, and is 56% in sample 2. The
identified sequence is shown in Figure 4(B).
Distribution of AGD3 in rat brain
In situ hybridisation
Figure 5 shows a photomicrograph of the neuroanatomical distribu-
tion of AGD3 mRNA. AGD3 mRNA was detected in several areas of
the hypothalamus, including the ARC, and ventromedial nucleus
(VMH). AGD3 mRNA was also observed in the amygdala, including
the central and basolateral subnuclei of the amygdala, as well as in
the hippocampus and the somatic cortex.
Figure 6 shows a photomicrograph of double in situ hybridisa-















































Fig. 1. Up-regulation of adipogenesis down-regulating transcript 3 (AGD3)
mRNA in arcuate nucleus neurones by fasting and obesity. (A) AGD3 mRNA
was significantly increased in fasted rats compared to fed rats (n = 5). (B)
Compared with lean Zucker rats, AGD3 mRNA was significantly increased in
obese Zucker rats (fa/fa) (n = 5). AGD3 mRNA levels were measured by a























































Fig. 2. (A) Specificity of adipogenesis down-regulating transcript 3 (AGD3)
antibody. Various cell lines and rat hypothalamus were lysed with lysis buffer
and supernatants were detected by western blotting using the anti-AGD3
antibody. This antibody detected a strong band in human embryonic kidney
(HEK) cells transfected with AGD3-pcDNA3.1, whereas no detectable signal
was found in HEK cells without transfection. AGD3 is also present in colorec-
tal adenocarcinoma (CACO-2) cells, neuroblastoma (SK-N-AS) cells and the
rat hypothalamus. (B) Up-regulation of AGD3 protein expression in the arcu-
ate nucleus by fasting. AGD3 was measured by western blotting using the
anti-AGD3 antibody. Each group comprised five animals. *P < 0.05.
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middle portions of the hypothalamus from Bregma 2.12
to 3.8 mm were hybridised and counted for each co-localisation.
Both POMC and NPY neurones have clusters of silver grains over
them. Each slice has similar co-localisation. Overall, 85 ± 12% of
POMC and 44 ± 9% of NPY neurones express AGD3.
Immunohistochemistry
Immunohistochemistry revealed that AGD3 protein is present in the
ARC, VMH, amygdala, hippocampus and somatic cortex, correspond-
ing with its mRNA distribution. Double immunohistochemistry
showed that AGD3 is present in POMC neurones from both the
ARC and amygdala (Fig. 7).
Interaction with IRS4
To identify molecules that interact with AGD3, myc-AGD3
pcDNA3.1 was transfected into HEK293 cells. Cell lysates were
incubated with anti-Myc agarose beads or protein A beads plus
normal immunoglobulin G. The gel bands in AGD3 lanes that were
missing bands in control were sent to identify constituents by
mass spectrometry analysis. IRS4 was pulled down by anti-AGD3
antibody. To confirm this interaction, we performed co-immuno-
precipitation experiments using HEK293 cells that have endoge-
nous IRS4 expression. Myc-AGD3 was expressed in HEK293 cells.
The cell lysates were incubated with anti-Myc antibody conjugated
to agarose. Anti-IRS4 antibody was used to detect endogenous





































Fig. 3. Three small interfering (si)RNAs against different domains of adipo-
genesis down-regulating transcript 3 (AGD3) were transfected into colorectal
adenocarcinoma (CACO-2) cells. These siRNAs inhibited AGD3 mRNA (A),
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Fig. 4. Identification of human adipogenesis down-regulating transcript 3
(AGD3) protein sequence. (A) Anti-AGD3 antibody was linked to agarose
beads to pull down AGD3 protein. Eluates were separated by electrophoresis
and the bands, which were confirmed by western blotting, were analysed by
mass spectrometry. (B) Mass spectrometry identified the presence of AGD3
protein. The sequence depicted is a human hypothetical protein sequence,






Fig. 5. In situ hybridisation of adipogenesis down-regulating transcript 3
(AGD3) in rat brain. AGD3 mRNA is distributed in the arcuate nucleus (ARC),
ventromedial hypothalamus (VMH), amygdaloid nuclei (CeM and BLA), hip-
pocampus and somatic cortex.
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with AGD3; IRS4 was pulled down by anti-AGD3 antibody from rat
hypothalamus tissue (Fig. 8B). To examine whether IRS4 can pull
down AGD3, HEK293 cells were transfected Flag-IRS4-CMV plasmid
along with myc-AGD3 pcDNA3.1 DNA. AGD3 was pulled down by
IRS4 (Fig. 8C).
Involvement of the ADG3 in insulin signalling
Because AGD3 interacts with IRS4, which is an element in the insu-
lin signalling pathway, we investigated the role of AGD3 in Akt
phosphorylation, a component of insulin signalling. SK-N-AS cells
were transfected with AGD3 and Akt phosphorylation was exam-
ined. AGD3 expression in SK-N-AS cells significantly enhanced
insulin-stimulated Akt phosphorylation (Thr308) (Fig. 9A). When the
SK-N-AS cells were transfected with AGD3 siRNA for 72 h, insulin-
stimulated Akt phosphorylation (Thr308) was significantly inhibited.
The extent of inhibition was 28.6 ± 6% (Fig. 9B).
Involvement in AMPK and mammalian target of rapamycin
(mTOR) signalling pathway
The AMPK kinase and mTOR signalling systems are responsive to
cellular energy status and are involved in hypothalamic adaptation
to fasting and feeding. An AGD3 siRNA approach was used to
POMC (purple) and AGD3 (silver grains)
NPY (purple) and AGD3 (silver grains)
Fig. 6. Double in situ hybridisation of adipogenesis down-regulating tran-
script 3 (AGD3) in the rat arcuate nucleus. AGD3 mRNA is co-localised with
pro-opiomelanocortin (POMC) (upper panel) and neuropeptide Y (NPY) neu-
rones (lower panel). Blue represents digoxigenin-labelled POMC and NPY
neurones. Silver grains indicate AGD3 mRNA.
ARC
20 µm 20 µm
20 µm
10 µm10 µm
10 µm 10 µm
20 µm
Amygdala
Fig. 7. Co-localisation of adipogenesis down-regulating transcript 3 (AGD3)
with pro-opiomelanocortin (POMC) neurones in the arcuate nucleus (ARC)
and amygdala. Confocal photomicrographs of dual staining of AGD3 (green)
and POMC (red) shows the co-localisation of AGD3 with POMC. Nuclei are
stained with 4′,6-diamidino-2-phenylindole dihydrochloride.
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determine whether AGD3 interacted with these pathways. As shown
in Fig. 10, transfection of GT1-1 cells with AGD3 siRNA affected
these pathways differentially, decreasing AMPK phosphorylation
and increasing the expression of pP70 and pS6, which are the
downstream signal molecules in the mTOR signal pathway (14). This
result indicates that AGD3 up-regulates phosphorylation of AMPK
and inhibits mTOR pathway.
Discussion
The present study describes a novel 63-amino acid peptide, AGD3,
which is expressed in areas of the brain related to the control of
ingestive behaviour that interact with energy signalling pathways.
This conclusion is supported by distinct observations: (i) AGD3
mRNA is regulated by fasting and feeding in the hypothalamic
ARC; (ii) AGD3 encodes a novel 63-amino acid protein; (iii) the pro-
tein interacts specifically with insulin receptor substrate 4; (iv) the
protein is expressed in regions of the rat brain relevant to feeding
behaviour; (v) there is a high degree of overlap with brain areas
that also express insulin receptor substrate 4; and (vi) the protein
affects Akt, AMPK and mTOR-dependent signalling in vitro.
The novel protein characterised in the present study is derived
from a gene of approximately 1.2 kbp that has a high degree of
homology with the human OCC-1 gene first described by Pibouin
et al. (11). These investigators identified a novel human cDNA over-
expressed in a colon carcinoma cell line derived from a 29-year-old
woman with hereditary nonpolyposis colorectal cancer. The gene is
composed of six exons and is located in the q24.1 region of human
chromosome 12. Elevated levels of OCC-1 mRNA were observed in
three of eight colon carcinomas relative to normal mucosa from
the affected patient. However, no specific OCC-1 proteins were
detected.
The peptide characterised in the present study has also been
referred to as adipogenesis down-regulating transcript 3 (ADG3) by
Kikuchi et al. (12). These investigators used a panel of human bone





















































Fig. 8. Co-immunoprecipitation of adipogenesis down-regulating transcript
3 (AGD3) with insulin receptor substrate 4 (IRS4). (A) Myc-AGD3 vector was
transfected into HEK293 cells, which have endogenous IRS4 expression. Cell
lysates were immunoprecipitated with anti-Myc antibody-conjugated aga-
rose and blotted with anti-IRS4 antibody. (B) Normal rabbit immunoglobulin
(Ig)G or anti-AGD3 antibody were incubated with protein A beads and rat
hypothalamus tissue lysate. IRS4 was detected by anti-IRS4. (C) Flag-IRS4
and Myc-AGD3 vectors were co-transfected into HEK293 cells. Cell lysates
were precipitated with anti-Flag M2 beads and blotted with anti-Myc anti-
body. The membranes then were stripped and re-blotted with anti-Flag anti-
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Fig. 9. Enhancement of insulin-stimulated Akt phosphorylation by adipo-
genesis down-regulating transcript 3 (AGD3). (A) Neuroblastoma (SK-N-AS)
cells were transfected with myc-AGD3 pcDNA3.1. After 48 h of transfection,
10% serum Dulbecco’s modified Eagle’s medium (DMEM) was replaced with
serum-free DMEM containing 0.1% bovine serum albumin (BSA) and incu-
bated for another 2 h. Then, cells received insulin treatment for 20 min. (B)
SK-N-AS cells were transfected with AGD3 small interfering RNA2 for 72 h.
Cells were incubated with 0.1% BSA DMEM for 4 h, then, treated with insu-
lin for 20 min. Phosphorylation of Akt was detected by phospho-Akt anti-
body (Thr308).
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adipogenic and osteogenic induction in response to an array of
transcripts of unknown function. AGD3 strongly inhibited adipo-
genic induction in response to a medium containing insulin, dexa-
methasone, indomethacin and isobutylmethylxanthine. Polyclonal
antibody was prepared against the hypothetical human AGD3
protein. Western blotting confirmed that ADG3 expression was
reduced when hMSC were treated with AGD3 siRNAs, implying that
an intracellular peptide was produced by this transcript.
The present study is the first to describe the amino acid
sequence and localisation of this transcript in normal adult rat
brain tissues. AGD3 mRNA was detected in several regions of the
brain that are relevant to feeding behaviour. Within the hypothala-
mus, these include the ARC, and VMH. The ARC is a well-recognised
centre for the integration of peripheral and central signals that reg-
ulate appetite and metabolism (5). ARC neurones express receptors
for a variety of circulating factors, including insulin (15,16). AGD3
mRNA was also observed in the amygdala, the hippocampus and
the somatic cortex. The amygdala is primarily involved in emotions
such as fear, anger and pleasure, as well as memory (17,18). The
amygdala may also be involved in motivation and reward associ-
ated with eating (5,19). The amygdala sends projections to the lat-
eral hypothalamic area, and forms part of a circuit linked to
initiation of feeding (20–22).
In both the hypothalamus and amygdala, AGD3 mRNA was
detected in neurones that were positive for POMC peptide. The best
described anorexigenic neurones within the ARC express POMC and
CART. POMC neurones in the ARC play a key role in the regulation
of energy homeostasis. Two cleavage products of the POMC precur-
sor, a and b-melanocyte-stimulating hormones, inhibit food intake
and increase energy expenditure via melanocortin receptor subtypes
3 and 4 in the ARC, PVN and lateral hypothalamus (4,5). Efferent
projections from POMC/CART neurones to secondary energy homeo-
static neurones in intra- and extra-hypothalamic sites are key
features of energy homeostatic circuitry.
The AGD3 distribution in brain tissue showed a substantial over-
lap with that of IRS4. We have previously reported that IRS4 mRNA
is expressed in the ARC, VMH, dorsomedial nucleus, lateral hypo-
thalamus and amygdala (13). IRS proteins represent a family of
adapter proteins that play central roles in signal transduction by
insulin, insulin-like growth factor 2 and cytokines such as leptin
(23–25). Although the different IRS proteins vary in size, they share
structural and functional characteristics. The NH2-terminal of each
protein contains a homologous pleckstrin homology domain and a
phosphotyrosine binding region that mediate interactions with
insulin receptors. The COOH-terminal portion of each protein con-
tains tyrosine phosphorylation sites (26,27). Tyr-phosphorylated IRS
proteins serve as signalling scaffolds that propagate hormone
action through the binding of Src homology 2 domain-containing
proteins.
Although IRS4 is considered to have a role in signal transduction
similar to other members of the IRS family, the tissue distribution
of IRS4 is substantially different from that of other insulin receptor
substrates. The expression of IRS4 mRNA is restricted to the hypo-
thalamus in the brain, suggesting that IRS4 might be involved in
the regulation of energy homeostasis (28). In a previous study, we







































































































Fig. 10. The role of adipogenesis down-regulating transcript 3 (AGD3) in AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR)
signalling. Small interfering (si)RNA against AGD3 mRNA was transfected in mouse hypothalamus (GT1-1) cells for 72 h, and then starved for 4 h in serum-
free Dulbecco’s modified Eagle’s medium medium containing 1 mM glucose. Cell lysates were lysed with lysis buffer, and supernatants were used to detect
phosphorylation of AMPK (A), P70 S6 kinase (B) and S6 (C) by western blotting.NC1 negative control RNA was used as a control.
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The expression of IRS4 in POMC neurones implies that IRS4 may
function to mediate the action of insulin in these neurones.
Because IRS4 is a component of insulin signalling, the effect of
AGD3 expression on insulin signalling was examined. We investigated
the role of AGD3 in Akt phosphorylation using SK-N-AS cells that
were transfected with AGD3. AGD3 expression in SK-N-AS cells sig-
nificantly enhanced insulin-stimulated Akt phosphorylation (Thr308).
The AMPK kinase and mTOR signalling systems are responsive to
changes in organism and cellular energy status and have been
studied extensively in the hypothalamic control of feeding. An AGD
siRNA approach was used to determine whether AGD3 interacted
with these pathways. In GT1-1 cells treated with AGD3 siRNA,
AMPK phosphorylation was suppressed, whereas phosphorylation of
P70 and S6, comprising molecules in the mTOR signal pathway,
was increased.
In summary, AGD3 functions within the hypothalamic ARC as a
component of the insulin signalling pathway. The localisation of
AGD3 within both POMC-positive neurones and NPY-expressing
neurones, which have generally opposing actions in the regulation
of ingestive behaviour, further suggests that AGD3 may have a
central role in sensing organismal energy states. The regulation of
the AMPK and mTOR pathways by AGD3 is consistent with this
possibility and represents an area for further investigation.
Acknowledgements
The work was supported by NIH grants 2R01DK054032 and 5R37DK043225-20.
Received 16 March 2012,
revised 16 July 2012,
accepted 24 August 2012
References
1 Lam TK, Schwartz GJ, Rossetti L. Hypothalamic sensing of fatty acids.
Nat Neurosci 2005; 8: 579–584.
2 Sandoval D, Cota D, Seeley RJ. The integrative role of CNS fuel-sensing
mechanisms in energy balance and glucose regulation. Annu Rev Physiol
2008; 70: 513–535.
3 Woods SC, Lutz TA, Geary N, Langhans W. Pancreatic signals controlling
food intake; insulin, glucagon and amylin. Philos Trans R Soc Lond B
Biol Sci 2006; 361: 1219–1235.
4 Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central
nervous system control of food intake. Nature 2000; 404: 661–671.
5 Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central
nervous system control of food intake and body weight. Nature 2006;
443: 289–295.
6 Li JY, Kuick R, Thompson RC, Misek DE, Lai YM, Liu YQ, Chai BX, Hanash
SM, Gantz I. Arcuate nucleus transcriptome profiling identifies ankyrin
repeat and suppressor of cytokine signalling box-containing protein 4
as a gene regulated by fasting in central nervous system feeding
circuits. J Neuroendocrinol 2005; 17: 394–404.
7 Li JY, Lescure PA, Misek DE, Lai YM, Chai BX, Kuick R, Thompson RC,
Demo RM, Kurnit DM, Michailidis G, Hanash SM, Gantz I. Food depriva-
tion-induced expression of minoxidil sulfotransferase in the hypothala-
mus uncovered by microarray analysis. J Biol Chem 2002; 277: 9069–
9076.
8 Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N,
Oyama R, Ravasi T, Lenhard B, Wells C, Kodzius R, Shimokawa K, Bajic
VB, Brenner SE, Batalov S, Forrest ARR, Zavolan M, Davis MJ, Wilming
LG, Aidinis V, Allen JE, Ambesi-Impiombato A, Apweiler R, Aturaliya RN,
Bailey TL, Bansal M, Baxter L, Beisel KW, Bersano T, Bono H, Chalk AM,
Chiu KP, Choudhary V, Christoffels A, Clutterbuck DR, Crowe ML, Dalla
E, Dalrymple BP, de Bono B, Della Gatta G, di Bernardo D, Down T,
Engstrom P, Fagiolini M, Faulkner G, Fletcher CF, Fukushima T, Furuno
M, Futaki S, Gariboldi M, Georgii-Hemming P, Gingeras TR, Gojobori T,
Green RE, Gustincich S, Harbers M, Hayashi Y, Hensch TK, Hirokawa N,
Hill D, Huminiecki L, Iacono M, Ikeo K, Iwama A, Ishikawa T, Jakt M,
Kanapin A, Katoh M, Kawasawa Y, Kelso J, Kitamura H, Kitano H, Kollias
G, Krishnan SPT, Kruger A,Kummerfeld SK, Kurochkin IV, Lareau LF,
Lazarevic D, Lipovich L, Liu J, Liuni S, McWilliam S, Madan Babu M,
Madera M, Marchionni L, Matsuda H, Matsuzawa S, Miki H, Mignone F,
Miyake S, Morris K, Mottagui-Tabar S, Mulder N, Nakano N, Nakauchi H,
Ng P, Nilsson R, Nishiguchi S, Nishikawa S, Nori F, Ohara O, Okazaki Y,
Orlando V, Pang KC, Pavan WJ, Pavesi G, Pesole G, Petrovsky N, Piazza
S, Reed J, Reid JF, Ring BZ, Ringwald M, Rost B, Ruan Y, Salzberg SL,
Sandelin A, Schneider C, Schonbach C, Sekiguchi K, Semple CAM, Seno
S, Sessa L, Sheng Y, Shibata Y, Shimada H, Shimada K, Silva D, Sinclair
B, Sperling S, Stupka E, Sugiura K, Sultana R, Takenaka Y, Taki K, Tam-
moja K, Tan SL, Tang S, Taylor MS, Tegner J, Teichmann SA, Ueda HR,
van Nimwegen E, Verardo R, Wei CL, Yagi K, Yamanishi H, Zabarovsky E,
Zhu S, Zimmer A, Hide W, Bult C, Grimmond SM, Teasdale RD, Liu ET,
Brusic V, Quackenbush J, Wahlestedt C, Mattick JS, Hume DA, Kai C,
Sasaki D, Tomaru Y, Fukuda S, Kanamori-Katayama M, Suzuki M, Aoki J,
Arakawa T, Iida J, Imamura K, Itoh M, Kato T, Kawaji H, Kawagashira N,
Kawashima T, Kojima M, Kondo S, Konno H, Nakano K, Ninomiya N,
Nishio T, Okada M, Plessy C, Shibata K, Shiraki T, Suzuki S, Tagami M,
Waki K, Watahiki A, Okamura-Oho Y, Suzuki H, Kawai J, Hayashizaki Y,
Consortium F, Group RGER, Genome Science G. The transcriptional
landscape of the mammalian genome. Science 2005; 309: 1559–1563.
Erratum appears in Science. 2006 Mar 24;311(5768):1713.
9 Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet 2006; 15:
R17–R29.
10 Knowling S, Morris KV. Non-coding RNA and antisense RNA. Nature’s
trash or treasure? Biochimie 2011; 93:1922–1927
11 Pibouin L, Villaudy J, Ferbus D, Muleris M, Prosperi MT, Remvikos Y,
Goubin G. Cloning of the mRNA of overexpression in colon carcinoma-
1: a sequence overexpressed in a subset of colon carcinomas. Cancer
Genet Cytogenet 2002; 133: 55–60.
12 Kikuchi K, Fukuda M, Ito T, Inoue M, Yokoi T, Chiku S, Mitsuyama T, Asai
K, Hirose T, Aizawa Y. Transcripts of unknown function in multiple-
signaling pathways involved in human stem cell differentiation. Nucleic
Acids Res 2009; 37: 4987–5000.
13 Li J-Y, Chai B, Zhang W, Wu X, Zhang C, Fritze D, Xia Z, Patterson C, Mul-
holland MW. Ankyrin repeat and SOCS box containing protein 4 (Asb-4)
colocalizes with insulin receptor substrate 4 (IRS4) in the hypothalamic
neurons and mediates IRS4 degradation. BMC Neurosci 2011; 12: 95.
14 Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G. Mam-
malian TOR: a homeostatic ATP sensor. Science 2001; 294: 1102–1105.
15 Niswender KD, Baskin DG, Schwartz MW. Insulin and its evolving part-
nership with leptin in the hypothalamic control of energy homeostasis.
Trends Endocrinol Metab 2004; 15: 362–369.
16 Maejima Y, Kohno D, Iwasaki Y, Yada T. Insulin suppresses ghrelin-
induced calcium signaling in neuropeptide Y neurons of the hypotha-
lamic arcuate nucleus. Aging (Albany NY) 2011; 3: 1092–1097.
17 LeDoux J. The amygdala. Curr Biol 2007; 17: R868–R874.
18 Cardinal RN, Parkinson JA, Hall J, Everitt BJ. Emotion and motivation:
the role of the amygdala, ventral striatum, and prefrontal cortex. Neuro-
sci Biobehav Rev 2002; 26: 321–352.
© 2012 British Society for Neuroendocrinology Journal of Neuroendocrinology, 2013, 25, 292–301
300 B. Chai et al.
19 Baxter MG, Murray EA. The amygdala and reward. Nat Rev Neurosci
2002; 3: 563–573.
20 Petrovich GD, Setlow B, Holland PC, Gallagher M. Amygdalo-hypotha-
lamic circuit allows learned cues to override satiety and promote eating.
J Neurosci 2002; 22: 8748–8753.
21 Petrovich GD, Canteras NS, Swanson LW. Combinatorial amygdalar
inputs to hippocampal domains and hypothalamic behavior systems.
Brain Res Brain Res Rev 2001; 38: 247–289.
22 Elmquist JK, Elias CF, Saper CB. From lesions to leptin: hypothalamic
control of food intake and body weight. Neuron 1999; 22: 221–232.
23 White MF. IRS proteins and the common path to diabetes. Am J Physiol
Endocrinol Metab 2002; 283: E413–E422.
24 Wauman J, De Smet AS, Catteeuw D, Belsham D, Tavernier J. Insulin
receptor substrate 4 couples the leptin receptor to multiple signaling
pathways. Mol Endocrinol 2008; 22: 965–977.
25 Duan C, Li M, Rui L. SH2-B promotes insulin receptor substrate
1 (IRS1)- and IRS2-mediated activation of the phosphatidylinositol
3-kinase pathway in response to leptin. J Biol Chem 2004; 279: 43684–
43691.
26 Yenush L, Zanella C, Uchida T, Bernal D, White MF. The pleckstrin
homology and phosphotyrosine binding domains of insulin receptor
substrate 1 mediate inhibition of apoptosis by insulin. Mol Cell Biol
1998; 18: 6784–6794.
27 Yenush L, White MF. The IRS-signalling system during insulin and cyto-
kine action. BioEssays 1997; 19: 491–500.
28 Numan S, Russell DS. Discrete expression of insulin receptor substrate-4
mRNA in adult rat brain. Brain Res Mol Brain Res 1999; 72: 97–102.
© 2012 British Society for NeuroendocrinologyJournal of Neuroendocrinology, 2013, 25, 292–301
A novel transcript in hypothalamus enhances insulin signalling 301
